5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists
- 19 May 2003
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (10) , 1801-1804
- https://doi.org/10.1016/s0960-894x(03)00257-9
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Phenylacetic acid derivatives as hPPAR agonistsBioorganic & Medicinal Chemistry Letters, 2003
- The Mechanisms of Action of PPARsAnnual Review of Medicine, 2002
- New drug targets for type 2 diabetes and the metabolic syndromeNature, 2001
- New Perspectives into the Molecular Pathogenesis and Treatment of Type 2 DiabetesCell, 2001
- The PPARs: From Orphan Receptors to Drug DiscoveryJournal of Medicinal Chemistry, 2000
- Peroxisome Proliferator-Activated Receptors: Nuclear Control of MetabolismEndocrine Reviews, 1999
- Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPARδ Ligands Produce Distinct Biological EffectsJournal of Biological Chemistry, 1999
- PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytesAtherosclerosis, 1998
- Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured CellsJournal of Biological Chemistry, 1995
- Studies on antidiabetic agents. I. Synthesis of 5-(4-(2-methyl-2-phenylpropoxy)-benzyl)thiazolidine-2,4-dione (AL-321) and related compounds.CHEMICAL & PHARMACEUTICAL BULLETIN, 1982